PCOS (Polycystic Ovary Syndrome) Annual Evaluation Checklist

Why Annual Evaluation Matters in PCOS

PCOS is not a single-organ condition. It is a systemic endocrine disorder that touches metabolic health, cardiovascular physiology, reproductive function, and psychological well-being simultaneously. A once-at-diagnosis workup misses the disease's evolution across decades.

The 2023 International Evidence-Based Guideline for Assessment and Management of PCOS, developed jointly by the Monash University group and endorsed by the Endocrine Society, states explicitly that "ongoing monitoring for metabolic and cardiovascular risk factors is recommended at least annually in all women with PCOS" [1]. The AACE likewise includes PCOS among conditions requiring periodic metabolic reassessment [2].

The Lifespan Lens

Risk profiles change. An adolescent with PCOS may present with acne and irregular cycles but carry only modest metabolic burden. By her late 30s, cumulative anovulation, weight gain, and insulin resistance may have pushed her toward prediabetes or overt T2DM. Annual reviews catch that drift early.

Why Missed Diagnoses Persist

Population studies show women with PCOS wait an average of 2.3 years from first symptom to confirmed diagnosis [3]. Annual structured evaluations reduce the chance that a newly emerged complication goes unrecognized for another multi-year interval.

Metabolic Screening: The Highest-Yield Section of the Checklist

Insulin resistance and glucose dysregulation are present in 50 to 80% of women with PCOS regardless of BMI [4]. Every annual visit should include a structured metabolic panel.

Glucose and Insulin Testing

The Endocrine Society guideline recommends a 75-gram oral glucose tolerance test (OGTT) with fasting and 2-hour plasma glucose as the preferred screen, not fasting glucose alone, because postprandial dysglycemia is frequently the earliest abnormality in PCOS [1]. Fasting plasma insulin and a calculated HOMA-IR add clinical context, though they are not yet validated as standalone diagnostic thresholds.

HbA1c alone is insufficient for PCOS screening. A 2017 analysis published in the Journal of Clinical Endocrinology and Metabolism found HbA1c missed up to 40% of impaired glucose tolerance cases that the OGTT detected in women with PCOS [5].

Recommended glucose testing panel at each annual visit:

• Fasting plasma glucose
• 2-hour 75-g OGTT
• HbA1c (as a complement, not a replacement)
• Fasting insulin (for HOMA-IR calculation)

Lipid Panel

Dyslipidemia in PCOS typically presents as elevated triglycerides, reduced HDL-cholesterol, and a pattern of small dense LDL particles. A full fasting lipid panel, including LDL, HDL, total cholesterol, triglycerides, and ideally non-HDL cholesterol, should be ordered annually [2].

If the prior year's panel was normal and the patient is stable weight with no new cardiovascular risk factors, some guidelines permit biennial testing. Any weight gain exceeding 5% of body weight since the last visit resets that interval back to annual.

Blood Pressure and Anthropometrics

Measure blood pressure at every visit. Record weight, height, BMI, and waist circumference. A waist circumference above 88 cm in women of European ancestry (80 cm in Asian women) independently predicts metabolic syndrome severity in PCOS cohorts [6].

Hormonal and Reproductive Hormone Panel

Androgens

Total testosterone and free testosterone (or calculated free testosterone using SHBG) confirm the hyperandrogenic component and track treatment response. In women on oral contraceptives, SHBG rises and free testosterone falls, which may mask residual biochemical hyperandrogenism if only free testosterone is measured [1].

Anti-Müllerian hormone (AMH) reflects ovarian reserve and correlates with follicle count. AMH is not required at every annual visit, but reassessing it every 2 to 3 years provides a useful trend line, particularly in women approaching 35 who are planning future pregnancy.

Thyroid and Prolactin

TSH and prolactin are not PCOS markers, but hypothyroidism and hyperprolactinemia both mimic PCOS symptoms and must be excluded or monitored for de novo development. Annual TSH is clinically reasonable given the high prevalence of Hashimoto thyroiditis in young women. Prolactin needs only periodic rechecking unless symptoms suggest change [7].

LH, FSH, and Estradiol

These are not routine annual tests in established PCOS. Measure them if fertility status has changed, if symptoms suggest premature ovarian insufficiency, or if menstrual pattern has shifted substantially.

Cardiovascular Risk Assessment

Women with PCOS carry an approximately 2-fold higher risk of adverse cardiovascular events compared with controls, based on a 2011 meta-analysis of 6 studies covering more than 1,500 women [8]. The absolute risk is still low in younger patients, but the relative acceleration is real and warrants proactive monitoring.

Beyond the Lipid Panel

Standard 10-year cardiovascular risk calculators (ACC/AHA Pooled Cohort Equations) can underestimate risk in PCOS because they were not developed in PCOS-specific cohorts. Clinicians at the 2023 PCOS guideline consensus conference recommended considering PCOS as a risk-enhancing factor when using these calculators [1].

High-sensitivity CRP (hsCRP) is an optional add-on. Elevated hsCRP above 3.0 mg/L is found in a significant proportion of normal-weight PCOS patients, suggesting subclinical vascular inflammation independent of obesity [9].

Sleep Apnea Screening

Obstructive sleep apnea (OSA) occurs in 5 to 10 times the frequency in women with PCOS compared with age- and BMI-matched controls [10]. At each annual visit, ask about snoring, daytime sleepiness, and witnessed apneas. A STOP-BANG score of 3 or higher warrants referral for polysomnography.

Endometrial Health Monitoring

Chronic anovulation exposes the endometrium to unopposed estrogen. The relative risk of endometrial cancer in women with PCOS has been estimated at 2.7 (95% CI 1.0 to 7.3) in a Cochrane-cited systematic review [11].

When to Order Ultrasound

The 2023 guideline does not mandate annual pelvic ultrasound for every patient. Ultrasound is indicated when:

• The patient has not had a withdrawal bleed or spontaneous period in 90 days or longer
• Abnormal uterine bleeding develops at any point
• The prior ultrasound showed endometrial thickness above 7 mm in the follicular phase

For women on combined oral contraceptives with predictable withdrawal bleeds, annual ultrasound is not required.

Progestogen Protection

Women who menstruate fewer than 4 times per year should receive cyclical progestogen (e.g., medroxyprogesterone acetate 10 mg for 10 to 14 days every 1 to 3 months) to induce regular shedding and reduce endometrial hyperplasia risk [1]. Document menstrual frequency at every visit.

Mental Health and Quality-of-Life Screening

Depression prevalence in PCOS is approximately 3 times higher than in age-matched women without the condition, and anxiety prevalence is roughly 5 times higher [12]. These figures come from a 2018 systematic review and meta-analysis of 18 studies (N=3,050) published in Human Reproduction.

Validated Screening Tools

Use at least one validated instrument at each annual visit:

• PHQ-9 for depression
• GAD-7 for generalized anxiety
• PCOSQ (PCOS Questionnaire) or FertiQoL for health-related quality of life specific to the condition

A PHQ-9 score of 10 or above warrants formal psychiatric or psychological referral. Do not wait for the patient to raise the topic; screening must be proactive.

Body Image and Eating Disorders

Hirsutism, acne, and weight changes associated with PCOS significantly increase risk of disordered eating. The ESHRE/ASRM-sponsored PCOS consortium identified binge eating disorder as particularly prevalent in PCOS cohorts [13]. Ask specifically about eating behaviors using the EDE-Q brief screen or equivalent.

Fertility and Reproductive Planning Review

PCOS accounts for roughly 70 to 80% of anovulatory infertility cases [14]. Annual visits are the right time to formally document reproductive intentions and adjust management accordingly.

For Patients Not Currently Seeking Pregnancy

Confirm contraceptive status. Combined oral contraceptives remain first-line for cycle regulation and androgen suppression in women not pursuing conception [1]. Progestogen-only methods do not reliably suppress androgens and require a separate plan for endometrial protection.

For Patients Actively Seeking Pregnancy

Document ovulation status (basal body temperature charts, mid-luteal progesterone, LH testing). If spontaneous ovulation is absent, letrozole 2.5 to 7.5 mg on cycle days 3 to 7 is now the first-line ovulation induction agent per both the 2023 international guideline and the ASRM Practice Committee [1, 15]. Clomiphene citrate remains an acceptable alternative but carries higher rates of multiple gestation.

Metformin 1,500 to 2,550 mg/day, combined with letrozole, shows improved live birth rates compared with letrozole alone in women with PCOS and insulin resistance, based on the 2021 PCOSMIC trial [16].

Weight Management and GLP-1 Receptor Agonists in PCOS

Even a 5 to 10% reduction in body weight restores ovulation in 55 to 75% of overweight women with PCOS [17]. Weight management therefore deserves its own section in the annual checklist, not a footnote under metabolic labs.

Lifestyle Intervention Benchmarks

The American Diabetes Association and the Endocrine Society both recommend structured lifestyle intervention (hypocaloric diet plus 150 minutes per week of moderate-intensity exercise) as the foundation of PCOS weight management [1, 18]. Behavioral support programs that include cognitive behavioral therapy components achieve superior long-term adherence compared with diet advice alone.

GLP-1 Receptor Agonists: Off-Label but Evidence-Supported

GLP-1 receptor agonists, including liraglutide and semaglutide, are not FDA-approved specifically for PCOS, but a growing body of trial data supports their off-label use in women with PCOS who have not achieved adequate weight loss or metabolic improvement with lifestyle changes alone.

A 2022 randomized controlled trial (N=272) published in Human Reproduction found that liraglutide 1.8 mg/day over 32 weeks produced significantly greater reductions in BMI, free androgen index, and fasting insulin compared with metformin alone in overweight women with PCOS [19]. The SCALE Obesity trial (N=3,731) showed liraglutide 3.0 mg produced 8.0% mean weight loss at 56 weeks in a general obesity population [20]; PCOS subgroup analyses show broadly comparable responses.

Semaglutide 2.4 mg weekly achieved 14.9% mean weight loss at 68 weeks in the STEP-1 trial (N=1,961) vs. 2.4% with placebo (P<0.001) [21]. Case series and smaller trials in PCOS suggest that this magnitude of weight loss reliably restores ovulation and reduces androgen levels in anovulatory PCOS patients.

The HealthRX Annual Weight and GLP-1 Decision Framework

At each annual PCOS visit, assess:

1. Current BMI and year-over-year weight trend
2. Degree of insulin resistance (HOMA-IR, OGTT result)
3. Prior response to lifestyle intervention (minimum 3-month structured attempt documented)
4. Contraindications to GLP-1 therapy (personal or family history of medullary thyroid carcinoma, MEN2, pancreatitis)

If BMI is 27 or above with metabolic comorbidity, or 30 and above regardless, and lifestyle intervention alone has not achieved 5% weight loss over 3 months, GLP-1 therapy is a reasonable next step to discuss at that same visit. Do not defer that conversation to a separate referral unless the patient is actively pregnant.

Medication Review and Adherence Check

Annual visits must include a structured medication reconciliation.

Metformin

Metformin 1,000 to 2,550 mg/day remains the most commonly prescribed insulin sensitizer in PCOS. Check renal function (eGFR) annually in patients on metformin. If eGFR falls below 45 mL/min/1.73m², dose reduction is required; below 30 mL/min/1.73m², metformin is contraindicated per FDA labeling [22].

Combined Oral Contraceptives

Review blood pressure at every visit. After 3 to 5 years of continuous use, revisit whether the indication remains active and whether the patient's cardiovascular risk profile has shifted enough to warrant switching formulations.

Inositols

Myo-inositol 2 to 4 g/day is a supplement with a reasonable safety profile and modest evidence for improving insulin sensitivity and restoring menstrual regularity in PCOS. A 2021 Cochrane systematic review found myo-inositol improved clinical pregnancy rates compared with placebo (OR 1.89, 95% CI 1.16 to 3.09) in women with PCOS undergoing ART [23].

Complete Annual Evaluation Checklist at a Glance

Labs to order at every annual PCOS visit:

• Fasting plasma glucose
• 2-hour 75-g OGTT
• HbA1c
• Fasting insulin (HOMA-IR calculation)
• Full fasting lipid panel (LDL, HDL, TG, total cholesterol, non-HDL)
• TSH
• Prolactin (if symptomatic or prior abnormality)
• Total testosterone
• SHBG and calculated free testosterone
• CBC (if on metformin long-term, also check B12)

Physical measurements at every visit:

• Blood pressure (both arms on first annual visit)
• Weight, BMI, waist circumference
• Ferriman-Gallwey hirsutism score
• Acne severity grading

Screening assessments at every annual visit:

• PHQ-9 and GAD-7 mental health screens
• Sleep apnea screen (STOP-BANG)
• Eating disorder brief screen (EDE-Q)
• Reproductive intentions and contraceptive review
• Menstrual diary review (frequency, duration, volume)

Conditional tests (order when indicated):

• Pelvic ultrasound (absent periods >90 days, abnormal bleeding, prior thickened endometrium)
• AMH (every 2 to 3 years if fertility planning relevant)
• hsCRP (if cardiovascular risk enhancement assessment needed)
• Polysomnography (STOP-BANG ≥3)
• Vitamin D (if deficiency risk present; deficiency common in PCOS)